Amyloidosis (renal)

Renal amyloidosis is a serious progressive disease in cats characterized by the abnormal deposition of amyloid protein in the kidneys, leading to organ dysfunction and eventually kidney failure. Amyloid is an insoluble fibrous protein that accumulates in tissues when certain precursor proteins misfold and aggregate in ways the body cannot clear. In cats, this protein most commonly deposits in the kidneys, though the liver and other organs can also be affected. While amyloidosis can occur in any cat, it is particularly prevalent in certain breeds, most notably Abyssinians, Siamese, and Oriental Shorthairs, where it occurs as a familial condition with genetic inheritance patterns.

The development of amyloidosis in cats typically results from either genetic predisposition or chronic inflammatory conditions that trigger excessive production of amyloid precursor proteins. In hereditary forms, particularly the familial amyloidosis seen in Abyssinians, the condition develops due to inherited genetic mutations that cause overproduction or abnormal processing of amyloid proteins. In acquired forms, chronic infections, inflammatory diseases, or neoplastic conditions stimulate persistent production of serum amyloid A protein, which eventually converts to amyloid and deposits in tissues. Once amyloid accumulates in the kidneys, it progressively replaces normal tissue and impairs kidney function.

Renal amyloidosis has devastating effects on affected cats, causing progressive and irreversible kidney damage that ultimately leads to kidney failure. The amyloid deposits interfere with the kidneys' normal structure and function, preventing proper filtration of blood and regulation of fluid and electrolyte balance. As the disease progresses, cats develop signs of chronic kidney disease including increased thirst and urination, weight loss, decreased appetite, and eventual uremia. The condition can also cause nephrotic syndrome, characterized by severe protein loss in urine, fluid accumulation, and blood clotting abnormalities. Unlike some causes of kidney disease, the damage from amyloidosis cannot be reversed.

Unfortunately, there is no cure for renal amyloidosis in cats, and treatment focuses on managing symptoms and slowing progression. The prognosis is generally guarded to poor, particularly in cats with advanced disease or familial forms. Early detection through screening of predisposed breeds may allow earlier intervention and extended survival times. Treatment strategies borrowed from human medicine, including medications that may reduce amyloid production or deposition, are being explored in cats with variable results. Despite the serious nature of this disease, supportive care can maintain quality of life for affected cats during their remaining time, making veterinary partnership essential for optimal management.

The primary cause of renal amyloidosis in cats is the abnormal production and deposition of amyloid protein in kidney tissues. Amyloid forms when certain precursor proteins, most commonly serum amyloid A protein in cats, misfold into an abnormal beta-pleated sheet configuration that resists normal breakdown and clearance mechanisms. Once formed, amyloid fibrils are extremely stable and accumulate progressively, replacing normal tissue architecture. In familial amyloidosis, genetic mutations drive overproduction of amyloid precursor proteins or impair normal protein processing. In reactive amyloidosis, chronic inflammatory conditions trigger persistent elevation of serum amyloid A, eventually leading to amyloid deposition.

Genetic and hereditary factors play a crucial role in feline amyloidosis, particularly in predisposed breeds. Abyssinian cats have well-documented familial amyloidosis with apparent autosomal dominant inheritance, meaning only one copy of the abnormal gene is needed for disease development. The specific genetic mutation in Abyssinians has not been definitively identified, though research continues. Siamese and Oriental Shorthairs also show familial patterns of amyloidosis, though the inheritance may differ from Abyssinians. Cats from affected families have significantly higher risk of developing the disease, often at relatively young ages compared to acquired forms. Responsible breeding practices that avoid affected cats help reduce disease prevalence.

Environmental and inflammatory factors contribute to acquired forms of amyloidosis in cats. Any condition causing chronic inflammation can potentially trigger reactive amyloidosis, though this form is less common in cats than dogs. Chronic infections including feline infectious peritonitis, chronic abscesses, and long-standing bacterial infections stimulate ongoing production of inflammatory proteins. Systemic inflammatory diseases create persistent amyloid precursor elevation. Certain cancers, particularly plasma cell tumors, can produce abnormal proteins that form amyloid. However, in many cats with amyloidosis, no underlying inflammatory condition is identified, suggesting subclinical inflammation or genetic predisposition even in apparently sporadic cases.

Risk factors for developing amyloidosis include breed, family history, and presence of chronic inflammatory conditions. Abyssinians face the highest risk, with some studies suggesting up to 25% of cats from affected bloodlines may develop the disease. Siamese, Oriental Shorthairs, and their related breeds show elevated risk. Age of onset varies but is typically between one and five years in familial forms, while acquired forms may develop at any age following prolonged inflammatory stimulation. Sex predisposition has been reported in some studies but is not consistently observed. Cats with known family history of amyloidosis should be considered at elevated risk regardless of current health status.

The mechanism of amyloid deposition and kidney damage involves a progressive process that gradually destroys normal kidney architecture. Amyloid fibrils deposit in the spaces between kidney cells, starting in the glomeruli where blood filtration occurs. As deposits accumulate, they compress and displace functional kidney cells. The glomerular deposits cause protein leakage into urine, characteristic of nephrotic syndrome. Continued accumulation extends to other kidney structures, progressively replacing functional tissue with insoluble protein. The kidneys become firm and pale as amyloid replaces normal tissue. Blood flow through affected areas decreases, causing additional ischemic damage. This progressive, irreversible process ultimately leads to end-stage kidney failure.

Early warning signs of renal amyloidosis in cats are often subtle and may be present for extended periods before obvious illness develops. Initial symptoms frequently include mildly increased thirst and urination as kidney concentrating ability begins to decline. Weight loss may occur gradually, easily attributed to other causes in the early stages. Some cats develop a dull or rough coat due to poor nutrition or protein loss. Decreased appetite may be intermittent initially, with cats seeming normal between episodes of reduced eating. Because cats hide illness and these early signs are nonspecific, amyloidosis often progresses significantly before diagnosis, particularly in cats not being screened due to known breed risk.

Common symptoms of established renal amyloidosis reflect both kidney dysfunction and protein loss. Increased thirst and urination become more pronounced as kidney failure progresses. Weight loss accelerates despite adequate food intake due to protein wasting. Decreased appetite becomes persistent and severe. Vomiting may occur from uremia or gastrointestinal complications. Lethargy and weakness develop as waste products accumulate. Dehydration becomes evident despite increased drinking. In cats with severe protein loss, fluid accumulation in the abdomen or chest may develop, causing respiratory distress or abdominal distension. These symptoms reflect the dual impact of kidney failure and nephrotic syndrome.

Behavioral changes in cats with amyloidosis are often dramatic as the disease progresses. Affected cats become progressively less active, spending more time resting and showing decreased interest in play or normal activities. Social interactions diminish as cats withdraw and spend more time hiding. Appetite changes are common, with cats becoming increasingly selective or refusing food entirely. Some cats develop unusual behaviors such as eating litter, seeking unusual water sources, or vocalizing more than normal. Changes in litter box habits may include urinating outside the box, producing larger volumes, or having accidents. These behavioral changes reflect both the physical effects of kidney failure and overall declining wellbeing.

Physical signs observable during examination of cats with amyloidosis include poor body condition with muscle wasting despite normal or increased fat stores in some cases. Dehydration is often present even in cats drinking increased amounts. The coat may be dull, unkempt, or have a greasy texture. Pale gums may indicate anemia, a common complication of kidney disease. The kidneys may feel abnormal on palpation, either enlarged in early disease or small and irregular in advanced cases. Ascites, or fluid accumulation in the abdomen, may be detected in cats with severe protein loss. Oral ulcers and ammonia breath indicate advanced uremia. Swelling of the legs may occur with severe hypoalbuminemia.

Symptom progression in amyloidosis typically follows a gradual but relentless course as amyloid continues to accumulate and kidney function declines. Early symptoms of mild kidney dysfunction worsen over months to years, with the rate of progression varying between individual cats. Weight loss becomes severe, with cats losing significant muscle mass. Uremic symptoms including vomiting, oral ulcers, and neurological changes develop as kidney failure advances. Cats with nephrotic syndrome may develop worsening fluid accumulation and breathing difficulties. Some cats experience acute crises with sudden worsening from blood clots or severe fluid shifts. Without intervention, the disease progresses to end-stage kidney failure with severe uremia and declining quality of life.

Certain symptoms in cats with amyloidosis warrant emergency veterinary care. Sudden breathing difficulty may indicate fluid accumulation in the chest or a blood clot in the lungs, both serious complications of protein loss. Acute onset of paralysis or severe pain in the rear legs suggests arterial thromboembolism, a potentially fatal complication. Collapse, seizures, or unresponsiveness indicate severe metabolic derangement. Complete refusal to eat or drink for more than twenty-four hours in a known affected cat suggests significant progression. Severe vomiting or bloody vomit indicates serious gastrointestinal involvement. Any sudden change from baseline in a cat with known amyloidosis should prompt immediate veterinary evaluation.

Diagnosis of renal amyloidosis begins with clinical suspicion based on breed, symptoms, and initial test results. Veterinarians consider amyloidosis in any Abyssinian, Siamese, or Oriental Shorthair presenting with signs of kidney disease, particularly at younger ages. The history typically reveals gradually progressive symptoms of increased thirst, weight loss, and decreased appetite. Physical examination assesses overall condition, hydration, kidney size, and signs of fluid accumulation. The combination of kidney dysfunction with significant protein loss, especially in predisposed breeds, strongly suggests amyloidosis and guides further diagnostic testing.

Blood and urine tests provide essential information for diagnosing and staging amyloidosis. Blood chemistry reveals elevated kidney values including blood urea nitrogen and creatinine indicating kidney dysfunction. Serum protein levels are often abnormally low, particularly albumin, reflecting urinary protein loss. Cholesterol may be elevated as part of nephrotic syndrome. Complete blood count may show anemia from chronic kidney disease. Urinalysis typically reveals dilute urine and significant proteinuria, with protein-to-creatinine ratios often dramatically elevated. The combination of kidney dysfunction, low blood protein, high urine protein, and elevated cholesterol characterizes nephrotic syndrome highly suggestive of amyloidosis in predisposed breeds.

Definitive diagnosis of amyloidosis requires demonstration of amyloid deposits through specialized testing. Kidney biopsy examined with Congo red staining shows characteristic apple-green birefringence under polarized light, confirming amyloid presence. However, kidney biopsy carries risks in cats with kidney disease and protein loss, limiting its use. Fine needle aspirates of the kidney may sometimes reveal amyloid but are less reliable than biopsy. In some cases, biopsy of other affected organs such as liver may be safer. Abdominal ultrasound may show changes suggestive of amyloidosis but cannot provide definitive diagnosis. Many cases are diagnosed presumptively based on clinical presentation in predisposed breeds without tissue confirmation.

Differentiating amyloidosis from other causes of protein-losing kidney disease is important for prognosis and treatment planning. Glomerulonephritis, immune-mediated kidney disease, can produce similar clinical pictures but may respond to immunosuppressive therapy. Other causes of chronic kidney disease typically cause less severe proteinuria. Systemic diseases including infections, inflammatory conditions, and cancers can cause both kidney disease and protein loss. The signalment is important, as familial amyloidosis typically affects young to middle-aged cats of predisposed breeds, while acquired forms or other diseases may have different age distributions. Thorough diagnostic workup helps distinguish these conditions.

Once amyloidosis is diagnosed or strongly suspected, staging disease severity guides management and provides prognostic information. Kidney function is assessed using International Renal Interest Society staging based on creatinine levels. The degree of proteinuria is quantified and categorized. Blood pressure measurement identifies hypertension requiring treatment. Assessment for complications including anemia, electrolyte abnormalities, and hypercoagulability guides supportive care. Baseline parameters establish reference points for monitoring disease progression. This comprehensive evaluation enables the veterinary team to develop individualized treatment plans and provide owners with realistic expectations regarding prognosis and quality of life.

Treatment for renal amyloidosis in cats is primarily supportive and symptomatic, as no therapy exists to reverse amyloid deposition or restore damaged kidney tissue. Initial management focuses on stabilizing cats that present with acute illness. Intravenous fluid therapy corrects dehydration and helps manage kidney values. Antiemetic medications control nausea and vomiting. Nutritional support through appetite stimulants or feeding tubes addresses anorexia. Treatment of any concurrent conditions such as infections or inflammatory diseases may help slow amyloid production in reactive cases. Severely affected cats may require intensive hospitalization initially before transitioning to outpatient management.

Medical management of the kidney disease component follows standard protocols for chronic kidney disease. Therapeutic kidney diets with restricted phosphorus and moderate protein help reduce uremic toxin production and protect remaining kidney function. Phosphorus binders control hyperphosphatemia when dietary restriction alone is insufficient. Potassium supplementation addresses losses common in kidney disease. Subcutaneous fluid therapy at home helps maintain hydration and kidney perfusion. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers may help reduce proteinuria and provide kidney protection. Blood pressure medications control hypertension that develops with kidney disease. Erythropoietin-stimulating agents treat anemia in severely affected cats.

Specific treatments targeting amyloidosis itself have limited evidence in cats but are sometimes attempted. Colchicine, which has shown benefit in some human amyloidosis cases, has been used in cats with variable results. This medication may help reduce inflammation and slow amyloid production but carries risks of toxicity and gastrointestinal side effects. Dimethyl sulfoxide has been proposed as a treatment that might dissolve amyloid deposits, but evidence for efficacy is limited. Immunosuppressive medications may be tried if an underlying inflammatory condition is identified. These treatments should be considered investigational and discussed thoroughly with veterinary specialists familiar with their risks and potential benefits.

Addressing complications of amyloidosis is a critical component of management. Nephrotic syndrome with severe hypoalbuminemia may require plasma transfusions in acute situations. Anticoagulant therapy with low-dose aspirin or other medications may be recommended due to the increased thromboembolism risk associated with protein loss. Aggressive diuretic therapy may be needed for cats with significant fluid accumulation causing respiratory distress. Management of concurrent liver amyloidosis, when present, adds complexity to treatment. Careful monitoring for complications and prompt intervention when they occur can improve quality of life even when the underlying disease cannot be cured.

Supportive and palliative care becomes increasingly important as amyloidosis progresses. Nutritional support through highly palatable foods, appetite stimulants, and assisted feeding maintains body condition as long as possible. Anti-nausea medications and antacids improve comfort and food intake. Pain management addresses discomfort from kidney disease or complications. Environmental modifications ensure comfortable resting areas and easy access to resources. Quality of life assessment guides decisions about treatment intensity and helps families recognize when their cat's comfort can no longer be maintained.

Treatment decisions in amyloidosis require balancing potential benefits against treatment burden and realistic expectations. The disease is progressive and ultimately fatal, though the timeline varies considerably between cats. Early intervention in mildly affected cats may extend survival significantly. Aggressive treatment of severely affected cats may not meaningfully improve outcomes while adding stress and expense. Breed, age, overall condition, severity of kidney dysfunction, presence of complications, and family circumstances all influence treatment recommendations. Veterinarians work closely with families to make decisions that prioritize the cat's quality of life while respecting individual values and resources. Hospice and end-of-life care should be discussed early to allow families time to prepare.

Recovery from amyloidosis in the traditional sense is not possible, as the disease is progressive and the kidney damage irreversible. However, many cats experience stabilization with appropriate management, and the timeline from diagnosis to end-stage disease varies considerably. Cats diagnosed early with mild kidney dysfunction may remain stable for months to years with proper supportive care. Those presenting with advanced disease have shorter expected survival times, typically weeks to months. The goal of management is not cure but rather maximizing quality time through symptom control and slowing progression when possible.

Post-diagnosis care involves establishing routines for ongoing management that can be maintained at home. Learning to administer subcutaneous fluids becomes essential for most affected cats, and most owners can master this technique with proper instruction. Medication schedules must be established and maintained consistently. Dietary transition to appropriate kidney-supportive nutrition requires patience but is important for disease management. Regular monitoring schedules are established, with initial frequent rechecks gradually extending as cats stabilize. Owner education about signs of complications empowers families to seek care promptly when problems arise.

Prognostic factors in feline amyloidosis include the severity of kidney dysfunction at diagnosis, degree of proteinuria, presence of complications, and response to initial treatment. Cats diagnosed with mild to moderate kidney disease generally survive longer than those presenting in advanced failure. Severe proteinuria carries a worse prognosis due to both its indication of extensive kidney involvement and associated complications. Development of thromboembolism dramatically worsens prognosis. Cats that stabilize well with initial treatment and maintain appetite often do better than those with persistent symptoms. Family commitment to consistent medical management influences outcomes through ensuring appropriate care delivery.

Long-term outlook for cats with amyloidosis should be discussed honestly while maintaining hope for quality time remaining. Median survival times reported in studies range from months to over a year depending on disease severity at diagnosis. Some cats remain comfortable and maintain good quality of life for extended periods with dedicated management. Others progress rapidly despite treatment. Regular quality of life assessments using standardized scales help families and veterinarians objectively evaluate how cats are doing. Planning for eventual decline, including discussions about end-of-life care preferences, helps families prepare while focusing present efforts on maintaining comfort and enjoyment during the time remaining.

Primary prevention of hereditary amyloidosis centers on responsible breeding practices in affected breeds. Abyssinian, Siamese, and Oriental Shorthair breeders should be aware of amyloidosis prevalence in their lines and avoid breeding cats from affected families. Genetic testing, as it becomes available, will help identify carriers and affected cats before breeding decisions are made. Prospective owners of predisposed breeds should research breeders' knowledge of and attention to amyloidosis in their programs. While prevention of the genetic forms requires decisions at the breeding level, individual cat owners can focus on early detection through screening rather than true prevention.

Reducing risk factors for acquired amyloidosis involves minimizing chronic inflammatory conditions. Prompt treatment of infections prevents prolonged inflammatory stimulation. Management of chronic diseases that might trigger reactive amyloidosis helps reduce risk. Good overall health maintenance through proper nutrition, appropriate veterinary care, and stress reduction supports immune function without excessive inflammation. However, given that most feline amyloidosis cases are familial rather than reactive, these measures have limited impact on overall disease prevention compared to breeding practices.

Dietary considerations for cats at risk of amyloidosis focus on general kidney health support. Ensuring adequate hydration through wet food diets and multiple water sources supports kidney function. High-quality protein sources without excessive protein intake provide nutrition without stressing kidneys. Avoiding supplements or additives that might stress kidneys or cause inflammation is prudent. Maintaining healthy body weight reduces metabolic demands on all organs. However, no specific dietary intervention has been proven to prevent amyloidosis in genetically predisposed cats.

Regular health monitoring is crucial for early detection in predisposed breeds. Annual blood work and urinalysis starting at one to two years of age allows early identification of kidney dysfunction or proteinuria. More frequent monitoring, perhaps every six months, may be recommended for cats from affected bloodlines. Screening allows intervention at early disease stages when management may be most effective. Establishing baseline values when cats are healthy provides comparison points for detecting early changes. This screening approach represents the most practical prevention strategy available for individual cats at risk.

Early intervention when abnormalities are detected can slow disease progression. Starting kidney-supportive diets and other management strategies at early stages may extend the period of acceptable kidney function. Treating any concurrent conditions promptly reduces additional kidney stress. Close monitoring allows rapid response to changes in condition. While early intervention cannot cure amyloidosis, it represents the best opportunity to extend quality survival time in affected cats. Working closely with veterinarians familiar with the disease provides the best chance for optimal outcomes in cats at risk.

Daily management of cats with amyloidosis requires consistent attention to hydration, nutrition, and medication administration. Most affected cats require subcutaneous fluid therapy at home, typically administered every one to three days depending on individual needs. Learning proper technique for fluid administration and establishing a comfortable routine helps make this process manageable for both cat and owner. Medications must be given consistently, which may require creative approaches for cats that resist pills. Monitoring daily food and water intake provides important information about disease stability or progression.

Home environment modifications support the comfort and wellbeing of cats with amyloidosis and associated kidney disease. Multiple water sources throughout the home encourage drinking. Easily accessible litter boxes accommodate increased urination frequency and potential mobility limitations. Comfortable, warm resting areas help cats conserve energy and maintain body temperature. Reduced environmental stressors through stable routines and calm surroundings support overall wellbeing. Stairs or access to favorite elevated spots may need accommodation as weakness progresses. Creating a safe, comfortable environment helps maintain quality of life.

Maintaining quality of life is the primary goal of amyloidosis management. Despite their illness, cats can still enjoy interaction, gentle play, and environmental enrichment appropriate to their energy levels. Favorite activities should be accommodated as much as possible, with modifications as needed. Social bonds with family members remain important and should be nurtured. Regular quality of life assessments using tools like the HHHHHMM scale help objectively evaluate how cats are doing over time. Focusing on what cats can still enjoy rather than what they have lost maintains positive perspectives for both cats and families.

Ongoing monitoring and veterinary partnership are essential for optimal amyloidosis management. Regular blood work and urinalysis track disease progression and treatment effectiveness. Weight monitoring detects trends that might indicate problems. Communication between families and veterinary teams ensures early intervention when changes occur. Adjustments to treatment protocols based on monitoring results optimize care. Establishing clear parameters for when to contact the veterinarian empowers families to seek help appropriately. The relationship between caring families and knowledgeable veterinary teams provides the foundation for the best possible outcomes.

Caregiver support is vital for families managing cats with progressive, terminal illness. Understanding that amyloidosis cannot be cured helps set realistic expectations while focusing on quality of life. Connecting with other families managing similar conditions through online communities provides emotional support and practical advice. Financial planning for ongoing and eventual intensive care reduces stress when expenses arise. Processing grief about the eventual loss while the cat is still alive is natural and healthy. Self-care for caregivers ensures they can provide sustained, loving care throughout their cat's remaining time. Veterinary teams can provide resources and support for families navigating this difficult journey.

Abyssinian cats have the highest documented risk for familial amyloidosis among cat breeds. Studies have shown prevalence rates as high as 25% in some Abyssinian populations, with the disease representing a significant health concern for the breed. The condition in Abyssinians typically manifests between one and five years of age, affecting relatively young cats. The inheritance pattern appears to be autosomal dominant, meaning affected cats have a 50% chance of passing the disease to offspring. Abyssinian breeders have worked to reduce prevalence through careful selection, but the disease remains a concern in the breed.

Siamese and Oriental Shorthair cats also show significantly elevated risk for amyloidosis. The disease in these breeds may have different characteristics than in Abyssinians, with some reports suggesting liver involvement may be more prominent. Related breeds including Colorpoint Shorthairs and Balinese may share this susceptibility given their genetic relationship to Siamese. The exact prevalence in these breeds is less well documented than in Abyssinians, but the familial pattern is recognized. Other breeds occasionally reported with amyloidosis include domestic shorthairs and various purebreds, though whether these represent familial forms or acquired disease is often unclear.

Screening recommendations for breeds at risk of amyloidosis emphasize early and regular monitoring. Cats of predisposed breeds should have baseline blood work and urinalysis performed at one to two years of age, before typical disease onset. Annual or semi-annual screening thereafter allows early detection of developing disease. Screening should include kidney values, complete blood count, serum protein levels, and urine protein-to-creatinine ratio. Breeders of affected breeds should have breeding cats screened and consider removing cats from affected bloodlines from breeding programs. Genetic testing, as it becomes available, will provide powerful tools for identifying carriers and reducing disease prevalence through informed breeding decisions.

Several conditions commonly occur alongside renal amyloidosis or share features that complicate diagnosis. Chronic kidney disease from any cause produces similar clinical signs and requires differentiation from amyloidosis. Glomerulonephritis, immune-mediated kidney inflammation, causes protein loss similar to amyloidosis but may respond to immunosuppressive therapy. Hepatic amyloidosis often occurs concurrently with renal involvement, and affected cats may show signs of both kidney and liver disease. Systemic inflammatory conditions, infections, or cancers may underlie reactive amyloidosis and require identification and treatment. Managing these concurrent or underlying conditions is essential for optimal care of cats with amyloidosis.

Conditions producing similar symptoms to amyloidosis must be considered in the diagnostic process. Other causes of protein-losing nephropathy including glomerulonephritis and glomerulosclerosis present similarly. Feline infectious peritonitis can cause kidney involvement and protein loss. Lymphoma affecting the kidneys may produce comparable signs. Hyperthyroidism and diabetes can occur concurrently with kidney disease, complicating the clinical picture. Cardiac disease may contribute to kidney dysfunction. Thorough diagnostic evaluation helps identify the underlying cause and guides appropriate treatment strategies.

Complications of amyloidosis significantly impact management and prognosis. Thromboembolism, blood clot formation and lodging in arteries, is a major complication of severe protein loss. Clots commonly affect the aortic trifurcation, causing sudden rear leg paralysis, or the lungs, causing respiratory distress. Anemia develops from chronic kidney disease and may require treatment. Hypertension damages additional organs if uncontrolled. Gastrointestinal complications from uremia include ulceration and bleeding. Fluid accumulation in body cavities causes discomfort and breathing difficulties. Preventing and managing these complications is essential for maintaining quality of life in affected cats.